BACKGROUND: Cerebrotendinous xanthomatosis (CTX) is an autosomal recessive lipid storage disorder characterized by a heterogeneous presentation and a broad spectrum of clinical manifestations. Since early diagnosis and replacement therapy with chenodeoxycholic acid can prevent clinical deterioration, our aim was to develop a diagnostic tool to identify and treat CTX patients at an initial stage of the disease. METHODS: We devised a suspicion index, composed of weighted scores assigned to indicators such as family history characteristics and common systemic and neurological features, on the basis of a pooled analysis of selected international CTX series. The indicators were classified as very strong (score 100), strong (50) or moderate (25). The suspicion index was then applied retrospectively to our CTX population. RESULTS: Early systemic signs such as cataract, diarrhea and neonatal cholestatic jaundice were considered strong indicators, together with neurological features such as intellectual impairment, psychiatric disturbances, ataxia, spastic paraparesis and dentate nuclei abnormalities at MRI. Tendon xanthomas were regarded as very strong indicators, as was an affected sibling. A total score ≥ 100 warranted serum cholestanol assessment. Elevated cholestanol or a total score ≥ 200, with one very strong or four strong indicators, warranted CYP27A1 gene analysis. In our patients, age at diagnosis was 35.5 ± 11.8 years (mean ± standard deviation), whereas with the diagnostic tool it became 10.6 ± 9.8 years (p < 0.01). CONCLUSIONS: Our suspicion index provides a simple and inexpensive diagnostic tool allowing diagnosis and treatment of CTX before neurological disability occurs.
BACKGROUND:Cerebrotendinous xanthomatosis (CTX) is an autosomal recessive lipid storage disorder characterized by a heterogeneous presentation and a broad spectrum of clinical manifestations. Since early diagnosis and replacement therapy with chenodeoxycholic acid can prevent clinical deterioration, our aim was to develop a diagnostic tool to identify and treat CTXpatients at an initial stage of the disease. METHODS: We devised a suspicion index, composed of weighted scores assigned to indicators such as family history characteristics and common systemic and neurological features, on the basis of a pooled analysis of selected international CTX series. The indicators were classified as very strong (score 100), strong (50) or moderate (25). The suspicion index was then applied retrospectively to our CTX population. RESULTS: Early systemic signs such as cataract, diarrhea and neonatal cholestatic jaundice were considered strong indicators, together with neurological features such as intellectual impairment, psychiatric disturbances, ataxia, spastic paraparesis and dentate nuclei abnormalities at MRI. Tendon xanthomas were regarded as very strong indicators, as was an affected sibling. A total score ≥ 100 warranted serum cholestanol assessment. Elevated cholestanol or a total score ≥ 200, with one very strong or four strong indicators, warranted CYP27A1 gene analysis. In our patients, age at diagnosis was 35.5 ± 11.8 years (mean ± standard deviation), whereas with the diagnostic tool it became 10.6 ± 9.8 years (p < 0.01). CONCLUSIONS: Our suspicion index provides a simple and inexpensive diagnostic tool allowing diagnosis and treatment of CTX before neurological disability occurs.
Authors: Andrea Mignarri; Maria Teresa Dotti; Marina Del Puppo; Gian Nicola Gallus; Antonio Giorgio; Alfonso Cerase; Lucia Monti Journal: Neuroradiology Date: 2012-03-15 Impact factor: 2.804
Authors: Sara von Bahr; Ingemar Björkhem; Ferdinand Van't Hooft; Gunvor Alvelius; Antal Nemeth; Jan Sjövall; Björn Fischler Journal: J Pediatr Gastroenterol Nutr Date: 2005-04 Impact factor: 2.839
Authors: Belen Pilo; Gema de Blas; Maria Jesus Sobrido; Carmen Navarro; Francisco Grandas; Francisco J Barrero; Miguel Angel Moya; Adriano Jimenez-Escrig Journal: Muscle Nerve Date: 2011-04 Impact factor: 3.217
Authors: Ignacio Rubio-Agusti; Maja Kojovic; Mark J Edwards; Elaine Murphy; Hoskote S Chandrashekar; Robin H Lachmann; Kailash P Bhatia Journal: Mov Disord Date: 2012-11-02 Impact factor: 10.338
Authors: Andrea E DeBarber; Limor Kalfon; Ayalla Fedida; Vered Fleisher Sheffer; Shani Ben Haroush; Natalia Chasnyk; Efrat Shuster Biton; Hanna Mandel; Krystal Jeffries; Eric S Shinwell; Tzipora C Falik-Zaccai Journal: J Lipid Res Date: 2018-08-22 Impact factor: 5.922
Authors: Andrea Mignarri; Maria Teresa Dotti; Antonio Federico; Nicola De Stefano; Marco Battaglini; Irene Grazzini; Paolo Galluzzi; Lucia Monti Journal: J Neurol Date: 2017-03-21 Impact factor: 4.849
Authors: Francesca Rosini; Elena Pretegiani; Andrea Mignarri; Lance M Optican; Valeria Serchi; Nicola De Stefano; Marco Battaglini; Lucia Monti; Maria T Dotti; Antonio Federico; Alessandra Rufa Journal: J Physiol Date: 2017-03-14 Impact factor: 5.182
Authors: Vivek Appadurai; Andrea DeBarber; Pei-Wen Chiang; Shailendra B Patel; Robert D Steiner; Charles Tyler; Penelope E Bonnen Journal: Mol Genet Metab Date: 2015-10-26 Impact factor: 4.797